![Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial](https://munin.uit.no/bitstream/handle/10037/24029/article.pdf.jpg?sequence=5&isAllowed=y)
Munin: Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial
![PRADA Trial: Candesartan or Metoprolol for Preventing Cardiac Dysfunction During Adjuvant Breast Cancer Therapy | tctmd.com PRADA Trial: Candesartan or Metoprolol for Preventing Cardiac Dysfunction During Adjuvant Breast Cancer Therapy | tctmd.com](https://cf-images.us-east-1.prod.boltdns.net/v1/jit/5270290550001/a6fca177-b428-4756-be4f-d5c7ee817966/main/1280x720/9m15s61ms/match/image.jpg)
PRADA Trial: Candesartan or Metoprolol for Preventing Cardiac Dysfunction During Adjuvant Breast Cancer Therapy | tctmd.com
![Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/7fb84603-13eb-4ad1-8525-4250c9df1d5f/gr2_lrg.jpg)
Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study - The Lancet Oncology
Prada Receive a Complimentary 4-Pc. trial set with any large spray purchase from the Prada Candy fragrance collection & Reviews - Shop All Brands - Beauty - Macy's
![PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fbd375114c38c6feaefa42552dfdf20cb0070dd0/5-Figure1-1.png)
PDF] Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial | Semantic Scholar
![Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline) Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline)](https://pbs.twimg.com/media/E1gxLTUVIAQ3fqE.jpg)
Sanah Christopher on Twitter: "PRADA trial #ACC21 long-term👀 for 💊Metoprolol/Candesartan vs placebo in breast cancer adjuvant therapy ⭐️2yr follow up 🚫difference in EF⬇️ for Metoprolol/Candesartan vs placebo (EF ⬇️ low at baseline)
![Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial | Cardio-Oncology | Full Text Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial | Cardio-Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40959-021-00115-w/MediaObjects/40959_2021_115_Fig1_HTML.png)
Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial | Cardio-Oncology | Full Text
![Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21 Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21](https://pbs.twimg.com/media/E1gu7MIXsAE4ySO.png)
Tochi Okwuosa #equityinhealthcare on Twitter: "Late breaking clinical trials presentation of the PRADA trial of candesartan/metoprolol for cardiotoxicity prevention in breast cancer patients post doxorubicin by Dr. Siri Lagethon Heck #cardioonc #ACC21
![Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation](https://www.ahajournals.org/cms/asset/02c15eb9-4540-4421-90b1-846feb79107c/circulationaha.121.054698.fig01.gif)
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy ( PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol | Circulation
![Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download Geeta Gulati 1, Siri Lagethon Heck 1, Anne Hansen Ree 1, Pavel Hoffmann 2, Jeanette Schulz-Menger 3, Morten W Fagerland 2, Berit Gravdehaug 1, Florian. - ppt download](https://images.slideplayer.com/27/8955914/slides/slide_5.jpg)